Peringkat dalam Saham
#38932
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Harga Saham
$2.84
Terakhir disinkronkan: 2025-07-14
Kapitalisasi Pasar
$729.71K
Perubahan (1 hari)
-0.70%
Perubahan (1 tahun)
0.00%
Perdagangan OncoCyte Corporation (OCX)
Laba untuk OncoCyte Corporation (OCX)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari OncoCyte Corporation, laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk OncoCyte Corporation dari 2026 hingga 2026
Laba pada akhir setiap tahun
| Tahun |
Laba |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan |
Laba |
Perbedaan Laba |
Negara |
|
|
$5.27B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$3.01B |
-
|
BE
|